Blog Exposure - Dova Pharma Inked Agreement with Fosun Pharma for Distribution of Avatrombopag in Mainland China and Hong Kong
Stock Monitor: BioDelivery Sciences Intl. Post Earnings Reporting
LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) ("Dova"). If you want access to this report all you need to do is sign up now by clicking the following linkwww.active-investors.com/registration-sg/?symbol=DOVA as the Company's latest news hit the wire. On March 19, 2018, the Company announced that its wholly owned subsidiary, AkaRx, Inc., has inked an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd ("Fosun Pharma Industrial"), granting the latter exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong. Financial details of the transaction remain undisclosed. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for BioDelivery Sciences International, Inc. (NASDAQ: BDSI), which also belongs to the Healthcare sector as the Company Dova Pharma. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=BDSI
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Dova Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=DOVA
Fosun Pharma Industrial is a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma").
Terms of the Agreement
Fosun Pharma Industrial will make an upfront payment, milestone payments, and a fixed transfer price to Dova. Fosun Pharma Industrial will have the right to exclusively develop and commercialize and to assist AkaRx with the registration of avatrombopag for chronic liver disease (CLD) patients with thrombocytopenia in mainland China and Hong Kong. Fosun Pharma Industrial will also support the development of avatrombopag for expanded indications in mainland China and Hong Kong.
Fosun Pharma has the Resources to Assist Dova with Avatrombopag's Marketing Authorization in China and Hong Kong
Commenting on the agreement, Alex Sapir, President and Chief Executive Officer of Dova, stated that Fosun Pharma is a highly qualified partner, and Dova is happy to work with them as it looks to expand avatrombopag internationally.
Alex added that Fosun Pharma is a strong pharmaceutical company in China and a growing international player. They have the resources and experience to assist Dova with the marketing authorization process in order to maximize the distribution of avatrombopag in mainland China and Hong Kong.
FDA Accepted Avatrombopag's NDA with Priority Review
In November 2017, the New Drug Application (NDA) for avatrombopag was accepted for filing and was granted Priority Review by the United States Food and Drug Administration (FDA). Dova sought FDA approval of avatrombopag for the treatment of thrombocytopenia in patients with CLD who are scheduled to undergo a procedure. The submission was based on two identically-designed Phase-3 clinical trials - ADAPT 1 and ADAPT 2, in which avatrombopag met all primary and secondary endpoints with high statistical significance. The Prescription Drug User Fee Act (PDUFA) goal date for an FDA decision is May 21, 2018.
About Chronic Liver Disease
CLD in the clinical context is a disease process of the liver that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis. CLD refers to disease of the liver which lasts over a period of six months. It consists of a wide range of liver pathologies which include inflammation (chronic hepatitis), liver cirrhosis, and hepatocellular carcinoma.
About Avatrombopag
Avatrombopag is a second generation orally administered thrombopoietin receptor agonist (TPO-RA) which is intended to address the limitations of other existing treatments for thrombocytopenia. Avatrombopag met all primary and secondary endpoints in two identically-designed Phase-3 clinical trials - ADAPT 1 and ADAPT 2. Dova holds the worldwide intellectual property rights to avatrombopag for all current and future indications.
About Dova Pharmaceuticals, Inc.
Founded in 2016 and headquartered in Durham, North Carolina, Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet medical need. The Company's lead drug candidate, avatrombopag, is owned by AkaRx, a wholly owned subsidiary of Dova.
Stock Performance Snapshot
March 20, 2018 - At Tuesday's closing bell, Dova Pharma's stock advanced 4.76%, ending the trading session at $26.19.
Volume traded for the day: 188.56 thousand shares, which was above the 3-month average volume of 123.39 thousand shares.
Stock performance in the previous six-month period - up 0.11%
After yesterday's close, Dova Pharma's market cap was at $675.96 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
